Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase I Clinical Trial of UB-312

Vaxxinity, Inc. announced that the first patient with Parkinson’s disease has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase I clinical trial, following completion of Part A of the Phase I trial in healthy volunteers.